Stock listing

OTC:GNNSF GenScript Biotech Corporation Stock

US listing (OTC) of GenScript Biotech Corporation · home listing HKEX:1548

Follow GenScript Biotech Corporation into a list and get an email when it puts out news.

Share price · OTC:GNNSF

$3.53 USD -0.25 (-6.6%)

Close on Nov 20, 2026

Past year +96.4% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
$3.53 – $3.53 USDNov 20, 2026
Volume
241 sharesNov 20, 2026
Market cap
$8.05B USDAt the close on Nov 20, 2026 · price × 2.28B shares outstanding
52-week range
$1.30 – $6.55 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5,595 USDMedian day 100 shares · 25 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
GenScript Biotech Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:1548 · Home$27.76 HKD-3.08 (-10.0%)39,731,486$29.00$29.00$27.32$30.84Close on Nov 20, 2026
OTC:GNNSF$3.53 USD-0.25 (-6.6%)241$3.526$3.53$3.526$3.78Close on Nov 20, 2026
Frankfurt:G51€3.24 EUR-0.16 (-4.7%)—€3.16€3.24€3.16€3.40Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · OTC:GNNSF · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.500.000.0%$4.50$4.50$4.500
$4.500.000.0%$4.50$4.50$4.500
$4.500.000.0%$4.50$4.50$4.500
$4.500.000.0%$4.50$4.50$4.500
$4.500.000.0%$4.50$4.50$4.50250
$4.500.000.0%$4.50$4.50$4.500
$4.500.000.0%$4.50$4.50$4.500
$4.50+0.25+5.9%$4.38$4.50$4.38500
$4.250.000.0%$4.25$4.25$4.250
$4.250.000.0%$4.25$4.25$4.250
$4.25+0.075+1.8%$4.25$4.25$4.25250
$4.1750.000.0%$4.175$4.175$4.1750
$4.1750.000.0%$4.175$4.175$4.1750
$4.1750.000.0%$4.175$4.175$4.1750
$4.1750.000.0%$4.175$4.175$4.1750
$4.175+0.125+3.1%$4.182$4.182$4.175900
$4.05-0.48-10.6%$4.05$4.05$4.05175
$4.530.000.0%$4.53$4.53$4.53320
$4.53-0.97-17.6%$4.55$4.55$4.405,325
$5.50+0.30+5.8%$5.50$5.50$5.50153
$5.20-0.058-1.1%$5.27$5.275$5.201,238
$5.258-0.542-9.4%$5.258$5.258$5.258100
$5.80-0.55-8.7%$5.50$5.80$5.501,690
$6.35+0.55+9.5%$6.55$6.55$6.351,630
$5.80+0.28+5.1%$5.84$6.00$5.705,680
$5.52-0.18-3.2%$5.52$5.52$5.521,000
$5.70+0.175+3.2%$5.70$5.70$5.701,000
$5.525+0.175+3.3%$5.525$5.525$5.525500
$5.350.000.0%$5.35$5.35$5.350
$5.35+0.30+5.9%$5.35$5.35$5.35500
$5.050.000.0%$5.05$5.05$5.050
$5.05-0.60-10.6%$5.05$5.05$5.05363
$5.650.000.0%$5.65$5.65$5.650
$5.650.000.0%$5.65$5.65$5.650
$5.65+0.833+17.3%$5.30$5.65$5.308,595
$4.817+0.717+17.5%$5.09$5.09$4.8171,020
$4.100.000.0%$4.10$4.10$4.100
$4.100.000.0%$4.10$4.10$4.100
$4.100.000.0%$4.10$4.10$4.100
$4.100.000.0%$4.10$4.10$4.100
$4.100.000.0%$4.10$4.10$4.100
$4.10+0.10+2.5%$4.10$4.10$4.10100
$4.000.000.0%$4.00$4.00$4.000
$4.000.000.0%$4.00$4.00$4.000
$4.00-0.30-7.0%$4.00$4.00$4.00100
$4.30-0.35-7.5%$4.30$4.30$4.30100
$4.650.000.0%$4.65$4.65$4.650
$4.65+0.25+5.7%$4.60$4.65$4.5151,660
$4.40-0.10-2.2%$4.55$4.60$4.352,697
$4.500.000.0%$4.50$4.50$4.50460
$4.50+0.35+8.4%$5.00$5.00$4.4510,023
$4.15-0.45-9.8%$4.15$4.15$4.151,000
$4.60+0.60+15.0%$4.15$4.60$4.155,100
$4.00+0.14+3.6%$3.90$4.00$3.906,806
$3.860.000.0%$3.86$3.86$3.860
$3.86+0.16+4.3%$3.80$3.86$3.806,000
Ticker
OTC:GNNSF
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
OTC
Currency
USD

What changed lately

Latest news

All GenScript Biotech Corporation news

GenScript Biotech Corporation on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
21 in the last 12 months · 28 in all · newest Nov 10, 2026 · oldest 2025
Calls
1 call with a replay · 1 with a transcript · latest Aug 16, 2026
Decks
4 decks · latest August 2025

Where GenScript Biotech Corporation is listed

ListingExchangeCountryCurrency
HKEX:1548 金斯瑞生物科技 · Home listingHKEXHong KongHKD
gettex:G51gettexGermanyEUR
OTC:GNNSF · This pageOTCUnited StatesUSD
LS Exchange:A2ACSBLS ExchangeGermanyEUR
Lang & Schwarz:A2ACSBLang & SchwarzGermanyEUR
Tradegate:G51TradegateGermanyEUR
Frankfurt:G51FrankfurtGermanyEUR
Stuttgart:G51StuttgartGermanyEUR
Dusseldorf:G51DusseldorfGermanyEUR
Munich:G51MunichGermanyEUR

Valuation

EV/sales 7.8× against a median of 5.6×: 7th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$58.79B HKD
P/E
Loss
EV/sales
7.8×
EV/EBITDA
22.8×
Price/book
2.1×
Gross margin
57.6%
Operating margin
26.6%
Net margin
−55.5%
Debt to equity
0.1×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
GenScript Biotech Corporation · HKEX:1548US$8.08BUS$7.50Bn/a7.8×22.8×2.1×−55.5%0.1×n/a
Avantor, Inc. · NYSE:AVTRUS$10.06BUS$13.28B29.8×2.0×14.7×1.7×5.1%0.6×0.78
WuXi XDC Cayman, Inc. · HKEX:2268US$9.64BUS$8.87B43.5×10.0×33.5×5.7×24.9%0.1×n/a
Tempus AI, Inc. · NASDAQ:TEMUS$9.58BUS$8.99Bn/a6.0×n/a19.1×−12.5%0.0×2.51
Bruker Corporation · NASDAQ:BRKRUS$8.62BUS$10.22Bn/a2.9×64.4×3.7×−3.5%0.7×1.72
Pharmaron Beijing Co., Ltd. Class A · SZSE:300759US$8.52BUS$8.23B32.1×3.4×n/a3.4×11.1%0.1×n/a
Bio-Rad Laboratories, Inc. · NYSE:BIOUS$7.84BUS$7.38B7.7×2.8×71.0×1.0×39.5%0.2×0.72
Shenzhen New Industries Biomedical Engineering Co. Ltd. Class A · SZSE:300832US$7.51BUS$7.10B27.8×9.8×n/a5.3×37.2%0.0×n/a
Twist Bioscience Corporation · NASDAQ:TWSTUS$7.04BUS$6.46Bn/a14.1×n/a7.9×−28.3%0.0×2.77
Asymchem Laboratories (Tianjin) Co., Ltd. Class A · SZSE:002821US$6.83BUS$5.89B38.5×5.3×n/a2.6×15.9%0.0×n/a
Bachem Holding AG Class B · SIX:BANBUS$6.80BUS$6.99B38.4×8.4×29.7×4.0×21.4%0.1×n/a
Median of the othersUS$8.18BUS$7.80B32.1×5.6×33.5×3.9×13.5%0.1×1.72

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
45.43 HKD · Analysts' mean
EPS, year to Dec 2026
0.030 · 1 analyst
Revenue, year to Dec 2026
898.1M · 6 analysts

Team and board

OfficerRole
Allen GuoCEO of ProBio
Sherry ShaoRotating CEO (on duty) of GenScript BioTech Corp.
Phil ZhouChief Financial Officer of GenScript BioTech Corp.
Ray ChenPresident of GenScript Life Science Group
Kening LiGeneral Counsel and Chief Compliance Officer
Aylin Kosova BilginChief Marketing & Corporate Communications Officer
Kate GrusichSenior Corporate Communications Manager
Aixi BaiGeneral Manager of Bestzyme
Bhama ParimooHead of Global DEI
Martin RexroadGeneral Manager of US Site for GenScript

Events

Next results
Mar 15, 2027 (expected)

Calls

CallWhenStatus
GenScript Biotech (HKEX:1548) Q2 2026 Earnings CallSun, Aug 16, 2026 · 7:30 PM ETReplay

Results days

QuarterResultsShare move
Q2 2025Aug 16, 2025 · Before open+2.5%
Q2 2024Aug 29, 2024−0.2%
Q4 2021Mar 21, 2022+5.7%
Q4 2020Mar 26, 2021−4.9%

Open Events

Decks

DeckKindSlidesDate
H1 2025 Earnings PresentationEarnings24 slidesAugust 2025
42nd Annual J.P. Morgan Healthcare Conference (January 2024)Conference33 slidesJan 10, 2024
FY2022 Earnings PresentationEarnings25 slides2023
Investor Presentation (2018)Investor deck46 slides2018

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue959.5M594.5M560.5M625.7M511.1M390.8M273.4M231.0M152.6M114.7M
Cost of revenue406.3M322.4M289.9M321.6M207.6M135.0M93.1M72.5M48.1M38.5M
Gross profit553.2M272.1M270.6M304.1M303.5M255.9M180.3M158.5M104.6M76.2M
Research and development71.2M53.8M52.7M390.1M358.4M263.4M186.0M74.1M18.1M9.47M
Selling, general and administrative128.6M114.4M106.8M182.5M302.5M90.3M55.3M40.6M22.0M30.4M
Operating income255.2M9.28M26.2M-438.1M-494.0M-204.5M-131.3M5.11M39.6M24.9M
Depreciation and amortization74.0M73.9M74.0M64.2M47.8M32.9M20.6M12.9M7.00M5.39M
EBITDA329.3M83.2M100.2M-373.9M-446.2M-171.7M-110.7M18.0M46.6M30.3M
Interest expense17.3M8.03M27.5M13.3M2.38M1.42M781.0K52.0K988.0K10.0K
Income before tax-470.5M-170.8M168.9M-431.7M-496.4M-281.9M-113.7M22.7M38.5M32.5M
Income tax61.9M2.98M6.01M-3.72M4.58M-477.0K3.83M1.94M11.5M5.97M
Net income-532.8M2.96B-95.5M-226.9M-347.9M-204.9M-96.9M21.2M26.1M26.2M
Earnings per share, basic-0.241.36-0.05-0.11-0.17-0.10-0.050.010.020.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents173.6M132.0M1.45B1.02B1.18B629.1M252.4M494.6M123.9M136.5M
Short-term investments669.4M489.2M481.6M228.9M222.5M142.1M174.1M70.1M3.09M202.0K
Receivables133.9M118.7M218.8M104.3M142.4M165.7M87.6M67.8M255.4M20.0M
Inventory39.6M31.1M53.3M59.9M44.4M31.7M19.9M12.4M6.88M4.24M
Current assets1.06B835.0M2.35B1.76B1.64B993.2M554.0M679.5M397.9M163.9M
Property, plant and equipment646.9M499.0M379.2M265.6M158.0M80.5M43.7M
Goodwill1.37M1.34M1.36M2.55M14.2M14.1M15.2M15.3M1.47M1.38M
Total assets4.85B5.28B3.39B2.55B2.23B1.45B889.4M917.0M504.3M226.0M
Accounts payable36.8M29.8M40.0M55.8M30.2M23.4M17.6M11.2M8.15M4.35M
Current liabilities720.1M307.3M494.8M546.0M413.3M327.9M224.5M153.5M272.7M39.2M
Long-term debt017.3M287.2M261.0M121.1M1.26M1.75M
Total debt258.8M723.7M417.0M349.8M156.4M52.4M22.4M10.5M
Total liabilities876.3M954.9M1.34B1.18B846.2M631.8M517.1M423.7M275.9M42.0M
Shareholders' equity3.96B4.32B1.39B1.01B1.05B901.7M382.8M478.7M217.8M177.6M
Shares outstanding2.19B2.18B2.11B2.10B2.03B1.95B1.88B1.84B1.73B1.71B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations325.5M75.6M-286.9M-120.3M-136.8M-151.1M-30.0M307.7M21.4M33.3M
Capital spending-83.8M-147.9M-157.7M-216.1M-133.0M-121.9M-110.4M-70.8M-29.2M-8.55M
Free cash flow241.7M-72.3M-444.6M-336.4M-269.8M-273.0M-140.3M236.8M-7.85M24.7M
Cash from investing-172.0M-1.46B-357.7M-443.3M-212.5M-100.2M-208.6M-194.0M-36.5M-8.31M
Cash from financing-144.9M66.5M1.07B419.3M902.1M624.2M-2.78M257.3M2.04M8.49M
Dividends paid0-2.63M-2.63M
Share buybacks-225.1M13.5M1.03B423.3M951.2M-9.46M-7.77M-11.5M2.94M11.3M
Change in cash10.5M-1.31B422.4M-157.0M551.9M376.7M-242.2M370.7M-12.6M32.7M

Open Financials

Filings

Open Filings

Cap table

Built by 6ix from GenScript Biotech Corporation’s releases

Common shares
2,280,496,463
Fully diluted
2,280,496,463

Fully diluted

LineShares
Common shares2,280,496,463

Share count over time

CountShares
Nov 22, 20262,280,496,463

Open Cap table

Shareholders

Register

HolderSharesOf the companyAs of
Zhang Fangliang801M35.1%Sep 15, 2026
Jin Weihong801M35.1%Sep 15, 2026
Huang Lili801M35.1%Sep 15, 2026
Wang Luquan801M35.1%Sep 15, 2026
Hu Zhiyong801M35.1%Sep 15, 2026
Wang Ye801M35.1%Sep 15, 2026
GenScript Corporation800M35.1%Sep 15, 2026
FMR LLC166M7.3%Oct 12, 2026
Fidelity Canada Investors LLC165M7.2%Oct 12, 2026
Pandanus Associates Inc.165M7.2%Oct 12, 2026
All 18 holders
HolderSharesOf the companyAs of
Pandanus Partners L.P.165M7.2%Oct 12, 2026
483A Bay Street Holdings LP165M7.2%Oct 12, 2026
483A Bay Street Holdings Management LLC165M7.2%Oct 12, 2026
FIL Limited165M7.2%Oct 12, 2026
Hillhouse Investment Management, Ltd.160M7.0%Sep 30, 2026
Hillhouse Fund V, L.P.160M7.0%Sep 30, 2026
Hillhouse Investment Management V, Ltd.160M7.0%Sep 30, 2026
GNS Holdings Limited160M7.0%Sep 30, 2026

Funds

HolderSharesValueAs of
Vanguard Total International Stock Index Fund17.7MUS$40.8MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund17.2MUS$39.5MJul 31, 2026
iShares Core MSCI Emerging Markets ETF13.6MUS$23.6MMay 31, 2026
Emerging Markets Core Equity 2 Portfolio5.7MUS$13.1MJul 31, 2026
T. Rowe Price New Asia Fund5.26MUS$12.1MJul 31, 2026
iShares ESG Aware MSCI EM ETF4.14MUS$7.21MMay 31, 2026
iShares MSCI China ETF3MUS$5.22MMay 31, 2026
iShares MSCI Emerging Markets ETF2.87MUS$5MMay 31, 2026
Vanguard Ftse All-World Ex-Us Index Fund2.85MUS$6.55MJul 31, 2026
Fidelity Series Global ex U.S. Index Fund2.43MUS$5.59MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
The Emerging Markets Small Cap Series2.34MUS$5.39MJul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF2.01MUS$4.64MJul 31, 2026
iShares Core MSCI Total International Stock ETF1.93MUS$4.44MJul 31, 2026
Fidelity Emerging Markets Index Fund1.48MUS$3.4MJul 31, 2026
Schwab Emerging Markets Equity ETF1.47MUS$2.56MMay 31, 2026
Matthews China Fund1.35MUS$2.12MJun 30, 2026
Goldman Sachs Emerging Markets Equity Insights Fund1.24MUS$2.85MJul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF1.16MUS$2.68MJul 31, 2026
Dimensional Emerging Core Equity Market ETF1.08MUS$2.48MJul 31, 2026
Vanguard Total World Stock Index Fund1.02MUS$2.35MJul 31, 2026
Avantis Emerging Markets Equity ETF996KUS$1.74MMay 31, 2026
Nuveen Emerging Markets Equity Index Fund914KUS$2.1MJul 31, 2026
Fidelity Total International Index Fund741KUS$1.71MJul 31, 2026
T. Rowe Price China Evolution Equity Fund736KUS$1.69MJul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF692KUS$1.08MJun 30, 2026
Avantis Emerging Markets Value ETF670KUS$1.17MMay 31, 2026
Fidelity Global ex U.S. Index Fund640KUS$1.47MJul 31, 2026
Global X Genomics & Biotechnology ETF639KUS$1.12MMay 31, 2026
KraneShares MSCI All China Health Care Index ETF508KUS$792KJun 30, 2026
WisdomTree China ex-State-Owned Enterprises Fund454KUS$709KJun 30, 2026
Dimensional Emerging Markets Value Fund452KUS$1.04MJul 31, 2026
Fidelity ZERO International Index Fund410KUS$944KJul 31, 2026
iShares MSCI All Country Asia ex Japan ETF406KUS$934KJul 31, 2026
Goldman Sachs ActiveBeta(R) Emerging Markets Equity ETF395KUS$689KMay 31, 2026
iShares MSCI ACWI ETF390KUS$897KJul 31, 2026
Avantis Emerging Markets Equity Fund386KUS$673KMay 31, 2026
Fidelity SAI Emerging Markets Index Fund364KUS$838KJul 31, 2026
WisdomTree Emerging Markets ex-State-Owned Enterprises Fund358KUS$558KJun 30, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio354KUS$552KJun 30, 2026
iShares MSCI ACWI ex U.S. ETF324KUS$745KJul 31, 2026
Dimensional Emerging Markets Value ETF324KUS$746KJul 31, 2026
World ex U.S. Core Equity Portfolio316KUS$727KJul 31, 2026
Emerging Markets Equity Index Fund304KUS$477KJun 30, 2026
Vanguard ESG International Stock ETF282KUS$491KMay 31, 2026
Praxis International Index Fund244KUS$381KJun 30, 2026
iShares MSCI Emerging Markets Asia ETF240KUS$418KMay 31, 2026
College Retirement Equities Fund - Total Global Stock Account233KUS$365KJun 30, 2026
International Strategic Equity Allocation Fund160KUS$279KMay 31, 2026
State Street(R) SPDR(R) MSCI ACWI ex-US ETF152KUS$237KJun 30, 2026
Fidelity Flex International Index Fund146KUS$336KJul 31, 2026

This page holds 50 of 89 holders. Open Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Aixi BaiGeneral Manager of Bestzyme · Since at least Nov 5, 2026
Allen GuoCEO of ProBio · Since at least Nov 5, 2026
Aylin Kosova BilginChief Marketing & Corporate Communications Officer · Since at least Jan 29, 2026
Bhama ParimooHead of Global DEI · Since at least Nov 5, 2026
Kate GrusichSenior Corporate Communications Manager · Since at least Aug 18, 2026
Kening LiGeneral Counsel and Chief Compliance Officer · Since at least Nov 5, 2026
Martin RexroadGeneral Manager of US Site for GenScript · Since at least Nov 5, 2026
Phil ZhouChief Financial Officer of GenScript BioTech Corp. · Since at least Nov 5, 2026
Ray ChenPresident of GenScript Life Science Group · Since at least Jan 29, 2026
Sherry ShaoRotating CEO (on duty) of GenScript BioTech Corp. · Since at least Aug 18, 2026

Open People

Log in to ask 6ix AI your own questions about GenScript Biotech Corporation.